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Chronic obstructive pulmonary disease (COPD) is a progressive and debilitating lung
disease affecting primarily older adults. Incidence, morbidity and mortality from COPD are
increasing worldwide. The purpose of this study was to determine the associations between
age at baseline and markers of disease progression in COPD patients using data generated by
the Genetic Epidemiology of COPD (COPD Gene) study. Participants with COPD were
stratified by age (younger: age <65 years, elderly: age ≥ 65 years) and disease characteristics
(lung function, exercise tolerance, exacerbation history, and comorbidity burden) at baseline
and five-year follow up were compared between groups. Associations between age group and
changes in these measures were also assessed. Disease characteristics differed significantly
between elderly and younger COPD patients at both study visits. Elderly COPD patients had
worse lung function and more comorbidities than younger COPD patients, while younger
COPD patients reported more dyspnea and more frequent and severe exacerbations than
elderly COPD patients. Following covariate adjustment, elderly participants were less likely
than younger participants to develop new frequent exacerbations over the study period
(relative risk ratio (95% confidence interval): 0.42 (0.20, 0.87)). There were no other

significant associations between age group and markers of disease progression. These results
suggest that although elderly COPD patients exhibit evidence of more severe lung function
impairment than younger COPD patients, the rate of disease progression is similar between
elderly and younger patients. However, further exploration is needed to understand the
possible contribution of survivorship bias to this finding. Nevertheless, this study supports
the importance of early detection and early intervention to slow disease progression and
maximize both life expectancy and quality of life for COPD patients.
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BACKGROUND
Literature Review
Introduction
Chronic obstructive pulmonary disease (COPD) is a progressive and debilitating lung
disease characterized by obstructive airflow patterns and abnormal inflammatory response to
noxious stimuli.1 The risk for developing COPD is believed to emerge from complex
interactions between a susceptible genome and exposure to environmental and/or lifestyle
factors. By far the greatest risk factor for COPD is smoking; however, only about 20% of
smokers will develop COPD.2 In addition, 15-20% of COPD cases have been attributed to
workplace exposures.2 Exposure to air pollution, including industrial emissions and biomass
burning, childhood infections, and malnutrition are also emerging as important risk factors
for COPD.2,3 The debilitating effects of COPD arise as a result of the increasing lung
function impairment that accompanies disease progression, resulting in the hallmark
symptoms of COPD: dyspnea, cough, and increased sputum production. 4 These symptoms
are important drivers of the overall burden of COPD and are associated with significant
reductions in quality of life, including disruption of daily activities, increased anxiety and
depression levels, sleep disturbances, and increased risk of exacerbations. 4 COPD
exacerbations are acute periods of increased symptom severity from a patient’s normal state
that often result in increased medication use, emergency room visits and hospitalizations. 5
Frequency of exacerbations is an important determinant of health-related quality of life in
COPD patients and is also linked to the rate of lung function decline, morbidities, and
mortality risk.5 In addition to exacerbations, COPD is also linked with increased risk for
1

several comorbid diseases that compound the morbidity, resource use, and mortality risk
associated with COPD. These include lung cancer, cardiovascular diseases (coronary heart
disease, heart failure, arrhythmias, peripheral artery disease, and hypertension), diabetes
mellitus, osteoporosis, and gastroesophageal reflux disease (GERD). 6–9

Pathology
Several distinct disease processes contribute to airflow limitation in COPD including
small airway disease, emphysema, and chronic obstructive asthma. 9 The relative contribution
of each process to the disease phenotype varies between individuals, creating a spectrum of
COPD manifestations. Small airway disease is a disease process affecting the bronchi and
bronchioles and consists of two main components, first: acute inflammation and mucus
plugging of the small airways, and second: fibrosis, narrowing, and destruction of the small
airways.10 The first process is at least partially reversible, whereas the second is
irreversible.10 Emphysema is a pathological term describing a gradual process of destruction
of the lung parenchyma, including the alveoli.11 This process is irreversible and eventually
results in hyperinflation, loss of elastic recoil, loss of surface area for gas exchange, and
airflow limitation.11 There are two predominant phenotypes of emphysema: centrilobular
and panlobular. Centrilobular emphysema affects predominantly the upper lobes of the lung
and the apices of the upper and lower lobes.12 In contrast, panlobular emphysema is spread
diffusely throughout the lung and is frequently associated with Alpha-1 antitrypsin
deficiency.12 Finally, asthma is a disorder of the airways characterized by chronic
inflammation and hyper-responsiveness that contribute to recurrent episodes of wheezing,
2

breathlessness, coughing, and tightness of the chest.13 Asthma patients whose airflow
obstruction is not completely reversible are also considered to have COPD, though the
etiology of their disease is likely to be distinct from individuals with COPD related to small
airway disease and/or emphysema.13

Disease Classification and Assessment of Lung Function
The Global Initiative for Chronic Obstructive Lung Disease (GOLD) was initiated by
the National Heart, Lung and Blood Institute (NLHBI) and the World Health Organization
(WHO) in 1998 to generate and communicate consensus recommendations for the
management of COPD. 9 These recommendations are published as the Global Strategy for
Diagnosis, Management and Prevention of COPD, also called the GOLD report. The
evidence-based recommendations laid out in the GOLD report include the GOLD spirometry
grades for severity of airflow limitation. Spirometry is a technique for assessing lung
function via measurements of the volume and/or speed of air that can be inhaled and exhaled.
The two most important spirometry measurements in COPD are the forced expiratory volume
in one second (FEV1) and the forced vital capacity (FVC).9 Despite the utility of spirometry
measurements for diagnosing and quantifying airflow limitation in COPD patients, these
measurements do not correlate well with patient functional status, quality of life, or
mortality.14 Therefore, several additional assessments are commonly used in evaluating
COPD patients. These assessments include the Modified Medical Research Council Dyspnea
Scale (MMRC) for evaluation of dyspnea and the six-minute walk test for assessment of
functional status in COPD patients.14 The six-minute walk test has been shown to associate
3

well with quality of life, lung function, and mortality risk, with shorter distances being
associated with worse outcomes.15,16 One final assessment technique used with COPD
patients that is of particular interest to researchers is the use of computed tomography (CT)
scans to visualize and quantify gas trapping and emphysema. 17,18 Research in this field has
led to increased understanding of the heterogeneity that characterizes the patterns of lung
damage seen in COPD patients and has allowed identification of specific subgroups of
patients that may be more or less likely to benefit from therapeutic trials.

Aging and COPD
COPD is primarily a disease of the elderly (age ≥ 60-65 years) and both incidence
and prevalence increase with age.2,19,20 In particular, the incidence of COPD has been
estimated to increase almost ten-fold with aging, increasing from 0.78 cases per 1000 personyears at age 40-44 years to 6.82 cases per 1000 person-years at age 75-79 years. 21 Similarly,
the prevalence of COPD is about 3% among individuals less than 40 years of age and
increases to about 8% in individuals between 40 and 64 years of age. In individuals greater
than 65 years of age, COPD prevalence further increases to 14-20%. 2,19 The observation that
incidence (and prevalence) of COPD increases with age suggests a role for the aging process
in COPD pathogenesis.1,3 Aging is a biological process involving a gradual reduction in
homeostasis and increasing risk of disease and death. 22 In the lung, aging is accompanied by
structural and physiological changes that share features with the pathological changes seen in
COPD, including emphysematous changes, fibrosis, and chronic inflammation. 22
4

Significant dysregulation of the immune system and tissue repair processes are also believed
to be key features in the pathology of both aging and COPD. 1,22 Changes in tissue repair
processes known to occur with aging, including increases in markers of cellular senescence,
imbalances of extracellular matrix proteins and gene expression, mitochondrial dysfunction,
telomere shortening, and stem cell exhaustion have been observed in COPD lungs and
experimental models of COPD.20,22,23 Immunosenescence is the term used to describe the
characteristic changes in the immune system observed with aging. 1 Over time, the ability of
the immune system to respond adaptively to antigens diminishes. 1 To compensate for the loss
of adaptive immunity, the innate immune system becomes chronically activated, resulting in
a persistently pro-inflammatory state.1,23 Similar changes are also observed in individuals
with COPD; in particular, an impaired ability to suppress pro-inflammatory immune
responses.22–24 Both aging and COPD are also associated with accumulation of senescent
cells, which exhibit a senescence-associated secretory phenotype (SASP) characterized by
secretion of proinflammatory cytokines, chemokines, and matrix metalloproteinases. 23 This
combination of cellular mediators results in both autocrine effects and paracrine effects that
serve to amplify and spread senescence to surrounding cells.23 Interactions between the
SASP and a dysfunctional immune system result in inflammaging, accelerated aging and
development of age-associated diseases, such as COPD. 23

Despite evidence of anatomical and molecular similarities between the aging lung and
the lung affected by COPD, as well as associations between aging and COPD development,
relatively little is understood about whether or how COPD progression, in particular lung
5

function decline, exacerbations, and comorbidity burden, differs between age groups.
Previous research in two separate cohorts of COPD patients (the Genetic Epidemiology of
COPD or COPDGene study and the Evaluation of COPD Longitudinally to Identify
Predictive Surrogate Endpoints or ECLIPSE study) has demonstrated differences in disease
characteristics between older (age ≥65 years old) and younger (age <65 years old)
individuals with COPD.4,6,13 Older individuals tended to experience worse lung function as
indicated by lower FEV1 (COPDGene: 30% lower, p<0.001; ECLIPSE: 12% lower,
p<0.001). Older COPD patients also had a greater percentage of emphysema (COPDGene:
6% greater, p<0.001; ECLIPSE: 3% greater, p<0.001) and gas trapping (COPDGene: 11%
greater, p<0.001) on computed tomography scans. 4 Finally, elderly individuals with COPD
also tended to have a greater number of comorbidities, including hypertension, coronary
artery disease, congestive heart failure, diabetes, and gastroesophageal reflux disease
compared to younger individuals.4 However, these results are cross-sectional, and therefore
do not provide information on disease progression. To understand the effects of aging on
COPD progression, examination of longitudinal data is needed to determine the differences
in disease progression between elderly and younger COPD patients.

Innovation
To date, the literature provides relatively little information on how progression of
COPD differs between older and younger COPD patients. This information is important, as it
will allow clinicians to tailor treatment strategies to the potentially unique demands of elderly
versus younger patients. Research has demonstrated the importance of effective disease
6

management for reducing exacerbations and improving quality of life for COPD patients. 25
This study will utilize data generated by the Genetic Epidemiology of COPD (COPDGene)
study.26 The COPDGene study was undertaken to identify genetic factors associated with
COPD, to describe disease phenotype subgroups, and to assess the relationships between
genetic factors and disease phenotypes.26 This dataset includes baseline and five-year follow
up data on current and former smokers (at least 10 pack-year history of smoking) with and
without COPD. The data collected includes demographics, self-reported symptom scoring,
pre- and post- bronchodilator spirometry, and computed tomography scans. This longitudinal
data will allow for the assessment of disease progression from year 1 to year 5 and the
exploration of the effects of age on this progression.

Public Health Significance
The importance of COPD as a major public health issue is becoming increasingly
apparent as morbidity and mortality from COPD continue to increase worldwide. 27 In the last
30 years, mortality from COPD has increased by approximately 163% and COPD is now the
third leading cause of death worldwide.2,27 However, it is widely accepted that COPD is
significantly under-diagnosed, both in the early stages of disease and in advanced stages; thus
the true burden of disease is likely to be much higher. 3,27 COPD is also one of the few chronic
diseases for which mortality is increasing.21 Currently, the global annual death rate attributed
to COPD is estimated to be about three million people.9 Over the next 40 years, this number
is expected to increase to over five million COPD-related deaths a year. 9
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In the United States alone, an estimated 12-24 million people are living with COPD,
many of whom are undiagnosed.25 In addition to considerable reductions in quality of life,
COPD imposes a significant economic burden on society, costing approximately $4000 per
patient per year in the US.25 In 2010, this amounted to just over $50 billion: $32 billion in
direct, health-care related costs, and $20.4 billion in indirect costs related to the disabling
effects of COPD including lost wages of patients and their family caregivers, sick-leave, and
impaired work performance.25,28 An estimated 45%-75% of the direct costs of COPD are
attributed to physician and emergency room visits, hospitalizations, and increased medication
use due to COPD exacerbations.28 GOLD stage, number of comorbidities, and level of
dyspnea have also been identified as significant drivers of health care-related costs of
COPD.29,30

As a result of its chronicity, individuals with COPD often suffer its effects for many
years before dying prematurely due to disease complications. This results in significant loss
of productivity and life-years. The Global Burden of Disease Study estimates that chronic
respiratory diseases account for about 4.5% of global disability-adjusted life years (DALYs),
with COPD responsible for approximately 3.24% of global DALYs. 31 COPD also accounts
for approximately 3.64% of global years lived with disability and 3.1% of global years of life
lost.31

The results of this study are expected contribute to an improved understanding of disease
progression in COPD. Ultimately, these results are expected to have a positive impact by
8

reducing the burden of COPD through contributing to efforts to improve the quality of life
experienced by individuals with COPD.

Hypothesis and Specific Aims
The long-term goal of this research is to contribute to the understanding of COPD
disease pathogenesis and improve the quality of life for COPD affected individuals. The
immediate objective of the proposed research is to characterize the patterns of disease
progression (lung function decline, exacerbation history, and comorbidity status) in elderly
(age greater than 65 years) compared to younger (age between 45 and 64 years) COPD
patients and to assess the associations between age and changes in lung function and
exacerbation history among COPD patients.

The specific aim of this study was to determine the associations between age at
baseline and markers of disease progression (lung function decline, exacerbation history, and
comorbidity status) at follow up in COPD patients. The hypothesis for this aim was that
elderly (older than 65 years at baseline) COPD patients would exhibit accelerated patterns of
disease progression when compared to younger (age between 45 and 64 years at baseline)
COPD patients.
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METHODS
Study Design
This study utilized data collected as part of the COPDGene study
(www.copdgene.org), a multicenter observational study of 10,198 non-Hispanic white and
African-American individuals aged 45-80 years old with at least a 10 pack-year history of
smoking with (n=3,695) or without COPD (n=6437).26 Participants were initially enrolled
between November 2007 and July 2012, at which time baseline data was collected.
Participants then returned for a follow up visit (n=6,284) approximately five years after the
initial visit and data collection was repeated to allow assessment of disease progression. 26

Study Sample
Participants included in this analysis were those with COPD (diagnosed via
spirometry as described below) classified as GOLD Stage 2 – GOLD stage 4 (defined as
described below). Participants also must have had data available for both visit 1 and visit 2.
Of the 10,198 participants in the full cohort, 3,695 had COPD and 1,566 of these individuals
had data for both visits. Of these, 899 were less than 65 years of age and 667 were aged 65 or
older. Baseline characteristics of participants with COPD that were subsequently lost to
follow up compared to individuals with COPD who completed the study are summarized in
Table 1. Individuals lost to follow up were similar to study completers with respect to
demographics and smoking history. Although non-completers were significantly older on
average than individuals who completed the study (mean ± SD: 63.6 ± 8.8 vs 62.9 ± 8.1
years, p=0.02, respectively, Table 1), the actual magnitude of this difference was quite small.
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Similarly, individuals lost to follow up had greater pack year histories of smoking compared
to study completers (mean ± SD: 54.0 ± 29.3 vs 51.5 ± 24.8 pack years, p<0.001,
respectively, Table 1), but again, the magnitude of the difference was small. Across disease
characteristics examined, non-completers had significantly worse values compared to study
completers (longer duration of disease, lower FEV1 and FEV1 % of predicted, shorter 6minute walk distance, greater percent of emphysema and percent of gas trapping on CT
scans, greater proportions of individuals with higher GOLD and MMRC scores, greater
proportions of individuals with frequent and severe exacerbations, and lower BMI; Table 1).
Finally, completers and non-completers had similar frequencies of CAD, Diabetes, and
Asthma, but non-completers had greater frequencies of hypertension, CHF, and GERD
(Table 1).
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Table 1. Demographic and disease characteristics of study completers vs those lost to follow
up.

Demographics
Age (years)
Gender (male)
Race (non-Hispanic white)
Smoking History
ATS Pack Years
Smoking Status (current smoker)
Disease Characteristics
Duration of COPD (years)
FEV1 (L)
FEV1 (%predicted)
6 Minute Walk Distance (meters)
% Emphysema on CT
% Gas Trapping on CT
Final GOLD Score
2
3
4
MMRC Score
0
1
2
3
4
Frequent Exacerbations (yes)
Severe Exacerbations (yes)
BMI
Comorbidity Status
Hypertension (yes)
CAD (yes)
CHF (yes)
Diabetes (yes)

Completers
(N = 1566)

Lost to follow up
(N = 2129)

p-value*

62.9 (8.1)
860 (54.9%)
1219 (77.8%)

63.6 (8.8)
1193 (56.0%)
1636 (76.8%)

.02
0.50
0.47

51.5 (24.8)
649 (41.4%)

54.0 (29.3)
855 (40.2%)

<0.001
0.43

7.1 (7.1)
1.53 (0.58)
53.1 (15.5)
386.6 (109.2)
12.3 (11.4)
37.6 (18.4)

9.9 (9.1)
1.38 (0.66)
48.2 (19.4)
336.0 (124.9)
14.2 (13.9)
39.4 (21.9)

0.005
<0.001
<0.001
<0.001
<0.001
0.02
<0.001

898 (57.3%)
544 (34.7%)
124 (8.0%)

1027 (48.2%)
620 (29.1%)
482 (22.6%)

366 (23.5%)
244 (15.7%)
321 (20.6%)
433 (27.8%)
195 (12.5%)
227 (14.5%)
288 (18.4%)
28.4 (6.1)

385 (18.1%)
237 (11.2%)
337 (15.9%)
651 (30.7%)
513 (24.2%)
442 (20.8%)
550 (25.8%)
27.8 (6.4)

<0.001
<0.001
0.003

758 (48.4%)
148 (9.5%)
61 (3.9%)
192 (12.3%)

1114 (52.3%)
194 (9.1%)
137 (6.4%)
291 (13.7%)

0.02
0.73
0.001
0.21

0.001
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GERD (yes)
Asthma (yes)

504 (32.2%)
432 (31.0%)

612 (28.7%)
566 (29.6%)

0.02
0.51

*, p-value based on independent samples T-test (continuous data) or Chi-squared test
(categorical data). ATS: American Thoracic Society, FEV1: forced expiratory volume in 1
second, CT: computerized tomography scan, GOLD: Global Initiative for Obstructive Lung
Disease, MMRC: Modified Medical Research Council Scale for dyspnea, BMI: body mass
index, CAD: coronary artery disease, CHF: congestive heart failure, GERD:
gastroesophageal reflux disease.
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Ethical Considerations
As part of the original COPDGene study, written informed consent was obtained
from all study participants at the time of enrollment. All study procedures were approved by
the institutional review boards at the participating study centers. The current research was
approved by the Office of the Institutional Review Board at The University of Texas Health
Science Center at San Antonio (UT Health San Antonio) and the Committee for the
Protection of Human Subjects at the University of Texas Health Science Center at Houston
(UTHealth).

Measurements
To determine the associations between age at baseline and markers of disease
progression (lung function decline, exacerbation history, and comorbidity status) at follow up
in COPD patients, several measures of disease progression between baseline and five-year
follow up were compared between elderly versus younger COPD patients. All model
variables were chosen a priori by the investigators and based on review of the literature.

Measures of disease progression
As part of the original study, spirometry measurements were performed according to
American Thoracic Society Guidelines26,32. Spirometry measurements were performed pre
and post bronchodilator administration to assess the reversibility of any present airflow
limitation. Airflow limitation indicative of COPD was defined according to GOLD
guidelines as a postbronchodilator FEV1/FVC ratio of less than 0.7. 33 The severity of airflow
14

limitation was determined by the FEV1 percent predicted value (FEV1 % predicted,
calculated based on NHANES reference equations 34). The GOLD grading scale was then
used to assign severity grades, from least to most severe, as follows: FEV1 % predicted ≥ 80
= GOLD 1, 50 ≤ FEV1 % predicted < 80 = GOLD 2, 30 ≤ FEV1 % predicted < 50 = GOLD
3, and FEV1 % predicted < 30 = GOLD 4.33

To analyze the extent of emphysema and gas trapping on lung CT scans, the density
mask technique was used. The density mask technique is based on the differences in CT
attenuation between normal lung tissue, emphysematous tissue, and areas of nonemphysematous gas trapping.17,18,26 CT scans were obtained during full inspiration and full
expiration and the percent of low attenuation areas was calculated. For quantification of
emphysema, a Hounsfield unit (HU) threshold of -950 HU on inspiratory CT was used. For
quantification of gas trapping a HU threshold of -856 HU on expiratory CT was used. 12,17,18,26
Eight measures of disease progression in COPD were included in the analysis: FEV1
(clinically measured as previously described), GOLD score (assigned as previously
described), presence of severe exacerbations (self-reported yes or no to being hospitalized for
an exacerbation in the previous year), frequency of exacerbations in the previous year (selfreported frequency of exacerbations in the last year, categorized into: 0: 1 or fewer
exacerbations in the previous year or 1: ≥2 exacerbations in the previous year), Modified
Medical Research Council Dyspnea Scale (MMRC) score, 6-minute walk distance (clinically
measured according to the American Thoracic Society official guidelines 35), percent of
emphysema on CT scan (clinically measured as previously described), and percent of gas
15

trapping on CT scan (clinically measured as previously described). The change in these
measures was calculated as the difference from visit 1 to visit 2 (change = visit 2 – visit 1).
The changes in MMRC Dyspnea score and GOLD score were further classified as follows:
negative change (visit 1 > visit 2) = improved, zero change (visit 1 = visit 2) = stable, and
positive change (visit 1 < visit 2) = declined.

Covariates
The following covariates were also examined: gender (male or female), race (nonHispanic white, black/African American), body mass index (BMI, clinically measured),
American Thoracic Society pack-years of smoking (ATS pack-years, calculated based on
self-reported smoking history), smoking status (self-reported as: currently smoking, or not
currently smoking), duration of COPD (calculated based on self-reported age at physician
diagnosed COPD), and comorbidity status (self-reported yes or no for physician diagnosis of:
hypertension, coronary artery disease (CAD), congestive heart failure (CHF), diabetes,
gastroesophageal reflux disease (GERD), and self-reported asthma status (yes or no to
question: “have you ever had asthma?”)). The change in ATS pack-years, smoking status,
duration of COPD, and comorbidity status were also calculated as previously described. The
change in comorbidity status was then further classified as follows: negative change (visit 1
> visit 2) = resolved, zero change (visit 1 = visit 2) = stable, and positive change (visit 1 <
visit 2) = new diagnosis.

Statistical Analyses
16

Descriptive statistics (frequency and percentage, or mean and standard deviation, as
appropriate) were used to summarize the distribution of each variable in the study sample
stratified by age (age between 45 and 65 versus age 65 or greater), at each visit. Age groups
were compared at each visit using independent samples T-test for continuous data or Chisquared test for categorical data. Paired samples analyses (paired samples T-test for
continuous data or Stuart-Maxwell test for categorical data) were then used to summarize the
unadjusted change from visit 1 to visit 2 in each variable for each age group. To examine the
relationship between age group and disease progression, the change in each measure of
disease progression was regressed against age group using multinomial logistic (for
categorical variables) and multivariable linear (for continuous variables) regression analysis
techniques. Each model was adjusted for age at baseline and for the baseline values of the
previously described covariates. Variables not different between age groups at baseline or
follow up were excluded from the final models (BMI, CHF, diabetes, and GERD). For the
multinomial logistic regression models, the independence of irrelevant alternatives
assumption was assessed using the seemingly unrelated estimation (suest)-based Hausman
test. For the linear regression models, the normalcy of residuals assumption was assessed
using a normal quantile-quantile plot of the residuals, homoskedasticity of the residuals was
assessed by plotting the studentized residuals against the predicted values of Y, absence of
multicollinearity of the predictors was assessed using the variance inflation factor with a cutoff value of 5, and influential observations were assessed using Cook’s distance with a cutoff value of 1. All analyses were performed using Stata version 16 36.
17

Study Power
Based on the results of Parulekar et al 4, given a median difference in FEV1 of 0.3 L
between elderly and younger COPD patients, an estimated un-pooled standard deviation of
0.88, a sample size of 1566 with an alpha of 0.05 provided a power of 1.0 to detect a
difference in FEV1 between elderly and younger COPD patients.
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RESULTS
Demographic and disease characteristics by age group
The demographic and disease characteristics of participants less than 65 years of age
at baseline compared to participants 65 years of age or older at baseline (visit 1) and at 5-year
follow up (visit 2) are summarized in Table 2.

At baseline, the average age of participants in the age less than 65 years group
(younger) was 57.2 years (SD: 5.1 years) and the average age of participants in the age 65
years or greater (elderly) group was 70.7 years (SD: 3.9 years) (p<0.001, Table 2). The
elderly group contained a greater proportion of males and non-Hispanic whites compared to
the younger group (% males: 59.4% vs 51.6%, p=0.002; and % non-Hispanic white: 88.6%
vs 69.9%, p<0.001, respectively, Table 2). Elderly COPD patients had a greater pack year
history of smoking compared to younger COPD patients (mean ± SD: 56.1 ± 27.0 vs 48.1 ±
22.6, respectively, p<0.001, Table 2), but were less likely than younger COPD patients to be
current smokers (20.7% vs 56.8%, respectively, p<0.001, Table 2). Elderly COPD patients
had greater duration of COPD compared to younger COPD patients (mean ± SD: 9.9 ± 9.1 vs
7.1 ± 7.1 years, respectively, p<0.001, Table 2).

Elderly COPD patients tended to have worse lung function metrics compared to
younger COPD patients, however this trend did not hold for all lung function measures
studied. Elderly COPD patients had significantly lower FEV1 compared to younger COPD
19

patients (mean ± SD: 1.42 ± 0.52 L vs 1.62 ± 0.61 L, respectively, p<0.001, Table 2), but had
similar FEV1 % of predicted (mean ± SD: 52.5 ± 15.0 vs 53.5 ± 15.8, elderly vs younger,
p=0.18) and six minute walk distance (mean ± SD: 386.2 ± 103.6 m vs 386.9 ± 113.2 m,
elderly vs younger, p=0.9) compared to younger COPD patients. Similarly, elderly COPD
patients had greater percentage of emphysema (mean ± SD: 14.1 ± 11.1 % vs 10.8 ± 11.4 %,
elderly vs younger, p<0.001) and gas trapping (mean ± SD: 41.61 ± 17.4 % vs 34.45 ± 18.6
%, elderly vs younger, p<0.001) on CT scan compared to younger patients, but had similar
GOLD scores (score 2: 55.8% vs 58.5%, score 3: 36.4% vs 33.5%, score 4: 7.8% vs 8.0%,
elderly vs younger, respectively, p=0.477) to younger COPD patients. In contrast, elderly
COPD patients had a smaller proportion of individuals with high (3 or 4) MMRC scores
(score 3: 25.9% vs 29.2%, score 4: 9.2% vs 15.0%, p<0.001, elderly vs younger, respectively
p=0.001), and were less likely to experience frequent and/ or severe exacerbations (frequent
exacerbations: 12.0 % vs 16.4%, elderly vs younger, p=0.02; severe exacerbations: 13.6% vs
21.9%, elderly vs younger, p<0.001) compared to younger COPD patients. Finally, elderly
and younger COPD patients had similar BMIs (mean ± SD: 28.4 ± 5.5 vs 28.4 ± 6.5, elderly
vs younger, p=0.72).

With respect to comorbidities, greater proportions of elderly COPD patients had
hypertension (56.1% vs 42.8%, elderly vs younger, p<0.001) and CAD (14.5% vs 4.2%,
elderly vs younger, p<0.001), but fewer elderly participants had asthma (25.7% vs 34.9%,
elderly vs younger, p<0.001) compared to younger COPD patients. The proportions of
patients with CHF (3.4% vs 4.2%, elderly vs younger, p=0.43), diabetes (13.8% vs 11.1%,
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elderly vs younger, p=0.11), and GERD (33.6% vs 31.2%, elderly vs younger, p=0.31) were
similar between elderly and younger COPD patients.

At five-year follow up, similar differences between the age groups were observed for
demographic variables, smoking history, and comorbidity status (Table 2). Differences
between age groups in disease characteristics, including duration of COPD, FEV1, %
emphysema, % gas trapping, MMRC score, exacerbation history, and BMI were also similar
at five-year follow up to the differences between age groups seen at baseline (Table 2). In
contrast, FEV1 % predicted was higher in elderly participants compared to younger
participants at visit 2 (mean ± SD: 49.6 ± 15.9 vs 47.6 ± 16.7, elderly vs younger, p=0.02),
whereas FEV1 % predicted had been similar between groups at baseline. Similarly, whereas
six-minute walk distance was similar between age groups at baseline, by visit 2, six-minute
walk distance was lower in elderly participants compared to younger participants (mean ±
SD: 319.0 ± 130.2 m vs 334.3 ± 132.4 m, elderly vs younger, p=0.03). Finally, at visit 2,
elderly participants had slightly better GOLD scores compared to younger participants (score
2: 49.2% vs 47.7%, score 3: 38.5% vs 34.1%, score 4: 12.3% vs 18.1%, elderly vs younger,
respectively, p=0.005), whereas GOLD scores had been similar between age groups at
baseline.
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Table 2. Demographic and disease characteristics of each age group at baseline and followup.

Demographics
Age (years)
Gender (male)
Race (non-Hispanic
white)
Smoking History
ATS Pack Years
Smoking Status
(current smoker)
Disease
Characteristics
Duration of COPD
(years)
FEV1 (L)
FEV1 (%predicted)
6 Minute Walk
Distance (meters)
% Emphysema on
CT
% Gas Trapping on
CT
Final GOLD Score
2
3
4
MMRC Score
0
1
2
3
4
Frequent
Exacerbations (yes)

Visit 1
less than 65 65 or older
(N = 899)
(N = 667)

p-value*

Visit 2
less than 65 65 or older
(N = 899)
(N = 667)

p-value*

57.2 (5.1)
464 (51.6%)

70.7 (3.9)
396 (59.4%)

<0.001
0.002

62.7 (5.1)
76.1 (4.0)
464 (51.6%) 396 (59.4%)

<0.001
0.002

628 (69.9%)

591 (88.6%)

<0.001

628 (69.9%) 591 (88.6%)

<0.001

48.1 (22.6)

56.1 (27.0)

<0.001

50.0 (23.2)

56.8 (27.4)

<0.001

511 (56.8%)

138 (20.7%)

<0.001

378 (42.0%)

89 (13.3%)

<0.001

7.1 (7.1)
1.62 (0.61)
53.5 (15.8)
386.9
(113.2)

9.9 (9.1)
1.42 (0.52)
52.5 (15.0)
386.2
(103.6)

<0.001
<0.001
0.18

15.3 (9.1)
1.23 (0.49)
49.6 (15.9)
319.0
(130.2)

<0.001
<0.001
0.018

0.90

12.6 (7.2)
1.35 (0.57)
47.6 (16.7)
334.3
(132.4)

10.8 (11.4)

14.1 (11.1)

<0.001

13.0 (13.1)

15.2 (12.6)

0.002

34.45 (18.6)

41.61 (17.4)

<0.001
0.477

39.4 (20.2)

43.5 (18.9)

<0.001
0.005

526 (58.5%)
301 (33.5%)
72 (8.0%)

372 (55.8%)
243 (36.4%)
52 (7.8%)

429 (47.7%) 328 (49.2%)
307 (34.1%) 257 (38.5%)
163 (18.1%) 82 (12.3%)
0.001

197 (22.0%)
122 (13.6%)
180 (20.1%)
261 (29.2%)
134 (15.0%)

169 (25.4%)
122 (18.3%)
141 (21.2%)
172 (25.9%)
61 (9.2%)

147 (16.4%)

80 (12.0%)

0.02
22

0.026

<0.001
176 (19.6%)
101 (11.2%)
170 (18.9%)
283 (31.4%)
169 (18.8%)

135 (20.2%)
113 (16.9%)
109 (16.3%)
229 (34.3%)
81 (12.1%)

174 (19.4%)

80 (12.0%)

<0.001

Severe
Exacerbations (yes) 197 (21.9%) 91 (13.6%)
<0.001 200 (22.2%) 112 (16.8%)
BMI 28.5 (6.5)
28.4 (5.5)
0.721
28.2 (6.9)
27.9 (5.9)
Comorbidity
Status
Hypertension (yes) 384 (42.8%) 374 (56.1%) <0.001 471 (52.4%) 417 (62.5%)
CAD (yes) 51 (5.7%)
97 (14.5%)
<0.001
74 (8.2%) 115 (17.2%)
CHF (yes) 38 (4.2%)
23 (3.4%)
0.431
54 (6.0%)
47 (7.0%)
Diabetes (yes) 100 (11.1%) 92 (13.8%)
0.111
154 (17.1%) 119 (17.8%)
GERD (yes) 280 (31.2%) 224 (33.6%)
0.314
323 (35.9%) 234 (35.1%)
Asthma (yes) 279 (34.9%) 153 (25.7%) <0.001 279 (34.9%) 153 (25.7%)
*, p-value based on independent samples T-test (continuous data) or Chi-squared test

0.008
0.28

<0.001
<0.001
0.41
0.71
0.73
<0.001

(categorical data). ATS: American Thoracic Society, FEV1: forced expiratory volume in 1
second, CT: computerized tomography scan, GOLD: Global Initiative for Obstructive Lung
Disease, MMRC: Modified Medical Research Council Scale for dyspnea, BMI: body mass
index, CAD: coronary artery disease, CHF: congestive heart failure, GERD:
gastroesophageal reflux disease.
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Unadjusted change within each age group
The average change in demographic and disease characteristics within each age group
from baseline to follow up are summarized in Table 3. The time elapsed between study visits
was similar between age groups and no changes in the gender or race distributions of the
groups occurred (Table 3). Pack year history of smoking increased (p<0.001) for both elderly
(mean ± SD: 0.7 ± 1.9 years) and younger (2.0 ± 2.6 years) COPD patients. Changes in
smoking status also occurred in both age groups. In the younger age group, 16.9% of
participants quit smoking between visit 1 and visit 2 and 2.1% of participants restarted
smoking between visit 1 and visit 2. Similarly, in the elderly age group, 8.8% of participants
quit smoking between visit 1 and visit 2 and 1.5% of participants restarted smoking between
visit 1 and visit 2.

Both age groups experienced declines (p<0.001) in FEV1 and FEV1 % of predicted
between study visits (FEV1 mean ± SD: -0.27 ± 0.31 L in the younger age group and -0.20 ±
0.24 L in the elderly age group; FEV1 % of predicted mean ± SD: -6.0 ± 10.2 % in the
younger age group and -2.9 ± 8.8 % in the elderly age group), as well as significant
(p<0.001) decreases in six-minute walk distances (mean ±SD, younger group: -51.8 ± 124.6
m and in the elderly group: -66.8 ± 95.5 m). Between study visits, increases in the
percentage of emphysema and gas trapping on CT scans also occurred in both age groups (%
emphysema mean ± SD: 2.3 ± 0.2% in the younger age group and 1.3 ± 5.7% in the elderly
age group; % gas trapping mean ± SD: 5.9 ± 10.8% in the younger age group and 2.2 ± 9.0%
in the elderly age group, all p<0.001). Changes in participant GOLD scores between visits
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occurred in both age groups. In the younger age group, 5.1% of participants had an improved
(lower) GOLD score at visit 2 compared to visit 1 and 24.4% of participants had a worse
(higher) GOLD score at visit 2 compared to visit 1. In the elderly age group, 6.9% of
participants had an improved GOLD score at visit 2 compared to visit 1 and 17.8% of
participants had a worse GOLD score at visit 2 compared to visit 1. Similarly, 25.2% of
younger participants had an improved MMRC score at visit 2 compared to visit 1 and 34.1%
had a worse MMRC score at visit 1 compared to visit 2 (p=0.03, Table 3). In elderly
participants, 21.2% had improved and 36.5% had worse MMRC scores at visit 2 compared to
visit 1 (p<0.001., Table 3).

Changes in exacerbation frequency and severity tended to differ for younger vs
elderly participants. In the younger age group, 14.1% of participants began experiencing
frequent exacerbations and 11.1% of participants who previously experienced frequent
exacerbations ceased to experience these (p=0.07, Table 3). In contrast, in elderly
participants, 6.4% of participants began experiencing and 6.4% of participants ceased to
experience frequent exacerbations (p=1.0, Table 3). The reverse tended to be true for severe
exacerbations: in younger participants, 13.9% began to experience severe exacerbations and
13.6% ceased to experience severe exacerbations (p=0.85, Table 3). In elderly participants,
12.6% developed severe exacerbations and 9.4% ceased to experience severe exacerbations
(p=0.08, Table 3). In both age groups, BMI decreased (p<0.001) between visit 1and visit 2
(mean ± SD, younger group: -0.2 ± 3.4 and in the elderly group: -0.5 ± 2.8).
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Finally, with the exception of asthma (which did not change), significant changes in
comorbidity status occurred for both age groups (Table 3). In the younger age group, 13.8%
of participants received a new diagnosis of hypertension and 1.3% of participants’
hypertension resolved between visit 1 and visit 2 (p<0.001, Table 3). Likewise, in the elderly
group, 11.4% of participants received a new diagnosis of hypertension and 4.9% of
participants’ hypertension resolved between visit 1 and visit 2 (p<0.001, Table 3). 3.9% of
younger and 5.7% of elderly participants received a new diagnosis of CAD and 1.3% of
younger and 3.0% of elderly participants’ CAD resolved between visit 1 and visit 2 (p<0.001
and p=0.02 for younger and elderly groups, respectively, Table 3). Similar patterns occurred
for CHF: 3.1% of younger and 5.1% of elderly participants received a new diagnosis of CHF
and 1.3% of younger and 1.5% of elderly participants’ CHF resolved between visit 1 and
visit 2 (p=0.01 and p<0.001 for younger and elderly groups, respectively, Table 3). Changes
in diabetes status between visit 1 and visit 2 also occurred in both age groups. In the younger
age group, 8.1% of participants received a new diagnosis of diabetes and 2.1% of younger
participants’ diabetes resolved between visit 1 and visit 2 (p<0.001). In the elderly age group,
these numbers were 0.7% and 4.8%, respectively. Finally, GERD status did not change for
elderly participants (p=0.37, Table 3), but did change for younger participants (p=0.002,
Table 3). 13.6% of younger participants received a new diagnosis of GERD, and 8.8% of
younger participants’ GERD resolved between visit 1 and visit 2.
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Table 3. Average change in demographic and disease characteristics from baseline to follow
up within each age group

Demographics
Age (years)
Gender (male)
Race (non-Hispanic white)
Smoking History
ATS Pack Years
Smoking Status
no change
quit smoking
restarted smoking
Disease Characteristics
Duration of COPD (years)
FEV1
FEV1 (%predicted)
6 Minute Walk Distance
(meters)
% Emphysema on CT
% Gas Trapping on CT
Final GOLD Score
improved
stable
declined
MMRC Dyspnea Score
improved
stable
declined
Frequent Exacerbations
ceased to experience
no change
began to experience
Severe Exacerbations
ceased to experience

less than 65
(N = 899)

65 or older
(N = 667)

p-value

p-valueϮ

5.6 (0.8)
no change
no change

<0.001
1.00
1.00

5.4 (0.6)
no change
no change

<0.001
1.00
1.00

2.0 (2.6)

<0.001
<0.001

0.7 (1.9)

<0.001
<0.001

Ϯ

728 (81.0%)
152 (16.9%)
19 (2.1%)

598 (89.7%)
59 (8.8%)
10 (1.5%)

5.5 (0.8)
-0.27 (0.31)
-6.0 (10.2)

<0.001
<0.001
<0.001

5.4 (0.6)
-0.20 (0.24)
-2.9 (8.8)

<0.001
<0.001
<0.001

-51.8 (124.6)
2.3 (0.2)
5.9 (10.8)

<0.001
<0.001
<0.001
<0.001

-66.8 (95.5)
1.3 (5.7)
2.2 (9.0)

<0.001
<0.001
<0.001
<0.001

46 (5.1%)
634 (70.5%)
219 (24.4%)

46 (6.9%)
502 (75.3%)
119 (17.8%)
0.03

225 (25.2%)
364 (40.7%)
305 (34.1%)

<0.001
141 (21.2%)
281 (42.3%)
243 (36.5%)

0.07
100 (11.1%)
672 (74.7%)
127 (14.1%)

1.00
43 (6.4%)
581 (87.1%)
43 (6.4%)

0.85
122 (13.6%)

0.08
63 (9.4%)
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no change
began to experience

652 (72.5%)
125 (13.9%)
-0.24 (3.43)

520 (78.0%)
84 (12.6%)
-0.48 (2.76)

<0.001
BMI
<0.001
Comorbidity Status
<0.001
<0.001
Hypertension
new diagnosis 124 (13.8%)
76 (11.4%)
no change 737 (82.1%)
558 (83.7%)
resolved
37 (4.1%)
33 (4.9%)
<0.001
0.02
CAD
new diagnosis
35 (3.9%)
38 (5.7%)
no change 852 (94.8%)
609 (91.3%)
resolved
12 (1.3%)
20 (3.0%)
0.01
<0.001
CHF
new diagnosis
28 (3.1%)
34 (5.1%)
no change 859 (95.6%)
623 (93.4%)
resolved
12 (1.3%)
10 (1.5%)
<0.001
<0.001
Diabetes
new diagnosis
73 (8.1%)
5 (0.7%)
no change 807 (89.8%)
630 (94.5%)
resolved
19 (2.1%)
32 (4.8%)
0.002
GERD
0.37
new diagnosis 122 (13.6%)
68 (10.2%)
no change 697 (77.6%)
541 (81.1%)
resolved
79 (8.8%)
58 (8.7%)
1.00
Asthma
1.00
new diagnosis
0 (0%)
0 (0%)
no change 799 (100.0%)
595 (100.0%)
resolved
0 (0%)
0 (0%)
Ϯ, p-value based on paired samples T-test (continuous data) or Stuart-Maxwell test
(categorical data). ATS: American Thoracic Society, FEV1: forced expiratory volume in 1
second, CT: computerized tomography scan, GOLD: Global Initiative for Obstructive Lung
Disease, MMRC: Modified Medical Research Council Scale for dyspnea, BMI: body mass
index, CAD: coronary artery disease, CHF: congestive heart failure, GERD:
gastroesophageal reflux disease.
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Associations between age group and disease progression
The associations between age group and disease progression are summarized in Table
4. All models were adjusted for age at baseline, gender, race, American Thoracic Society
pack-years of smoking at baseline, smoking status at baseline, duration of COPD at baseline,
and for the presence of hypertension, coronary artery disease, and/or asthma at baseline. All
model assumptions were determined to be within acceptable limits. The younger age group
was used as the reference group for all models.

Being in the elderly age group versus the younger age group did not have an impact
on either the development of severe exacerbations (relative risk ratio (95% confidence
interval): 1.17 (0.59, 2.31)) nor on the resolution of existing severe exacerbations (0.83 (0.44,
1.58)) between visit 1 and visit 2. There was also no effect of age group on the resolution of
existing frequent exacerbations (relative risk ratio (95% confidence interval): 0.56 (0.27,
1.16)), but elderly participants were less likely than younger participants to develop new
frequent exacerbations (0.42 (0.20, 0.87)). Age group did not have a significant effect on
decline in GOLD score (relative risk ratio (95% confidence interval): 0.86 (0.35, 2.08)), nor
on improvement in GOLD score (relative risk ratio (95% confidence interval): 0.89 (0.52,
1.55)). There was also no association between age group and changes in MMRC scores from
baseline to follow up (overall model: p=0.57, relative risk ratio (95% confidence interval) for
improved MMRC score: 0.83 (0.46, 1.49) and for worse score: 0.93 (0.54, 1.60)). Similarly,
there was no effect of age group on decline in six-minute walk distance (overall model:
p=0.08; β-coefficient (95% confidence interval): -0.67 (-28.42, 27.08) meters) or on the
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increase in percent of emphysema on CT scan (overall model: p=0.22; β-coefficient (95%
confidence interval): -0.62 (-2.10, 0.86)) between visits. Finally, age group had no effect on
the increase in percent of gas trapping on CT scan from baseline to follow up (β-coefficient
(95% confidence interval): -2.34 (-5.09, 0.41)), or on the decline in FEV1 from baseline to
follow up (β-coefficient (95% confidence interval): -22.50 (-85.87, 40.86) ml).
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Table 4: Multivariable associations between age group and disease progression in the study
population.
Relative Risk
Ratio

β-coefficient

95% CI

Severe exacerbations
improved
1.17
0.59, 2.31
declined
0.83
0.44, 1.58
Frequent exacerbations
improved
0.56
0.27, 1.16
declined
0.42
0.20, 0.87
MMRC score
improved
0.83
0.46, 1.49
declined
0.93
0.54, 1.60
GOLD score
improved
0.86
0.35, 2.08
declined
0.89
0.52, 1.55
Six-minute walk
-0.67
-28.42, 27.08
distance (meters)
%Emphysema
-0.62
-2.10, 0.86
%Gas trapping
-2.34
-5.09, 0.41
FEV1 (ml)
-22.50
-85.87, 40.86
FEV1: forced expiratory volume in 1 second, GOLD: Global Initiative for Chronic Lung
Disease score, MMRC: Modified Medical Research Council Scale for dyspnea. All models
adjusted for age at baseline, gender, race, American Thoracic Society pack-years of smoking
at baseline, smoking status at baseline, duration of COPD at baseline, presence of
hypertension, coronary artery disease, and asthma. The younger age group is the reference
group for all models.
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DISCUSSION
The purpose of this study was to examine the relationship between aging and
progression of COPD in the longitudinal COPDGene cohort. The results suggest that elderly
individuals with COPD had worse lung function compared to younger individuals with
COPD as evidenced by lower FEV1, higher percent of emphysema, and greater percent of
gas trapping at both baseline and 5-year follow up. Although exercise tolerance was similar
between elderly and younger individuals at baseline, at 5-year follow up, exercise tolerance
was lower in elderly COPD patients compared to younger COPD patients. Elderly patients
also had greater frequencies of comorbidities including hypertension and coronary artery
disease than younger patients. These results are consistent with those of previous studies that
have suggested elderly COPD patients experience worse lung function, increased exertional
intolerance, and greater frequencies of comorbidities.19

Despite this cross-sectional evidence of worse lung function, elderly individuals were
less likely to experience severe and/or frequent exacerbations compared to younger
individuals and reported less dyspnea (lower MMRC scores) than younger individuals with
COPD. This apparently contradictory result may be explained by differences in individual
perceptions of dyspnea between older and younger COPD patients. Dyspnea, by definition, is
a subjective experience that is unique to every individual. 37 Current understanding of the
mechanisms of dyspnea and perception of dyspnea remains limited, but includes cortical
integration of complex sensory information from multiple sensory mechanisms within the
respiratory system.37 Previous research has suggested that perception of dyspnea is dampened
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in elderly individuals, which may be related to lower nerve conduction velocity or other
impairments in axon structure and function.38 Research has further suggested individuals
with decreased perception of breathlessness also tend to report fewer and less severe
exacerbations compared to individuals with greater sensitivity to breathlessness. 39 Together,
these results may help explain why elderly participants in this study reported less dyspnea
and fewer and milder exacerbations compared to younger participants.

Over the follow up period, both elderly and younger COPD patients experienced
clinically significant declines in lung function and exercise tolerance as well as increases in
the frequencies of comorbidities. These findings are consistent with the understanding of
COPD as a progressively debilitating disease.1 Changes in variables from visit 1 to visit 2
were predominantly consistent between younger and elderly COPD patients – if a variable
increased significantly in one age group, it tended to do the same in the other age group. The
main difference in disease progression within age groups was the magnitude of the change,
which tended to be larger in the younger group and smaller in the elderly group. One possible
explanation for this observation is that because the elderly group started out worse than the
younger group, there was relatively less opportunity for further decline in the elderly group
such that their condition remained compatible with continued participation in the study or
survival. Indeed, previous studies have suggested that lung function decline is faster early in
the disease course of COPD and slows in the more advanced stages of disease. 40
Furthermore, rapid decline in lung function, particularly in FEV1, has been associated with
increased risk of mortality, even in individuals with otherwise normal lung function.
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There were relatively few differences in the rates of change in lung function
parameters between elderly and younger COPD patients. Consistent with the previous result
that elderly individuals tended to experience less change over time than the younger age
group, individuals in the elderly age group were less likely to develop frequent exacerbations
compared to participants in the younger age group. Again, this finding is consistent with a
requirement for preserving a level of functioning compatible with continued study
participation and/or life. There were no other significant associations between age group and
measures of COPD progression. These results suggest that the biological process of aging,
per se, is not a major driver of lung function decline, exacerbation status, and/or development
of comorbidities during the course of COPD progression. Instead, it seems likely that another
distinct factor, with a role in both aging and lung pathology, such as integrity of the immune
system, may play a critical role in programming host susceptibility to COPD progression.

This research has to be interpreted in the context of several potential limitations. First,
the data captured as part of the COPDGene study relies on many self-reported measures,
which are subject to recall bias and other errors of memory. This is particularly an issue for
the analysis of comorbidities, many of which seem unlikely to resolve over the study period
(e.g. CHF, CAD, diabetes), but were nevertheless reported as such by some study
participants. Additionally, we could not examine associations between age and lung function
decline in individuals with COPD who never smoked, as this data was not available in the
dataset. Also, the racial/ethnic composition of the study population was limited to non34

Hispanic Whites and African Americans in order to ensure sufficient power for the original
analysis. Therefore, the results of the current analysis cannot be applied to non-smokers and
individuals of other racial/ethnic backgrounds. Finally, survivorship bias may be affecting
our results. Analysis of individuals lost to follow up suggests that indeed individuals lost to
follow up may have been experiencing more severe illness compared to the individuals that
completed the study. Therefore, it is possible that our sample consisted of relatively less
affected individuals who were able to attend both study visits and who may not be fully
representative of the entire population of COPD patients.

This study also has several important strengths. First, the metrics used to assess
disease progression, including the six-minute walk distance, MMRC scores, GOLD scores,
and spirometry measurements, are well-validated and well-standardized techniques often
used for these types of studies.9,26 Further, COPDGene coordinators put into place detailed
study protocols and quality assurance protocols to ensure study measurements were
implemented consistently and results were comparable across study sites. Finally, the
COPDGene study included a large cohort of participants with meticulously collected and
curated data, with relatively little missing data, allowing the present study to be adequately
powered, without the need to make imputations for missing data.

In conclusion, this study suggests that while elderly individuals with COPD exhibit
evidence of more severe lung function impairment, they tend to report less dyspnea and
fewer and less severe exacerbations compared to younger individuals with COPD. This
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pattern persists over time, although younger individuals tend to experience a greater
magnitude of decline in lung function measurements compared to elderly individuals.
Despite these findings, the data did not provide strong support for a role of aging in the
pathogenesis of COPD. However, the contribution of survivorship bias to these findings
remains unclear. Nevertheless, this study emphasizes the importance of early diagnosis and
early intervention to slow the progression of disease in order to preserve maximum life
expectancy and quality of life for individuals affected by COPD. Further research into what
other host factors, such as immune system integrity, may explain varying patterns of disease
progression in COPD patients is warranted.
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